Added to YB: 2026-08-12
Pitch date: 2026-08-09
REGN [neutral]
Regeneron Pharmaceuticals, Inc.
+1.95%
current return
Author Info
Notes From The Beauty Contest is a buy-side investor who thought it might be fun to write about stocks in their spare time and in their own way. Sign up for the newsletter.
Company Info
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide.
Market Cap
$78.3B
Pitch Price
$781.72
Price Target
N/A
Dividend
0.48%
EV/EBITDA
13.34
P/E
19.40
EV/Sales
4.07
Sector
Biotechnology
Category
growth
Regeneron's Hidden Moat
REGN (overview): Regeneron Genetics Center (RGC) is an underappreciated moat — a vertically integrated 3m+ person sequencing 'factory' (path to 10m, ambition 50m) driving non-linear rare-variant discovery. New FNIP1 metabolic target (60% lower cardiometabolic disease odds) shows scale advantage; ~50 targets into pipeline, 13+ undisclosed. RGC gives multi-year IP/informational head starts, executed via VelociSuite antibodies & Alnylam RNAi. Bear: scale ≠ medicines, targets may be undruggable, minimal revenue yet. Thesis: durable edge could force revisiting terminal value.
Read full article (8 min)